Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Acarix AB (publ) (7AC.F)

Compare
0.0185
+0.0054
+(41.22%)
As of April 9 at 9:49:50 PM GMT+2. Market Open.
Loading Chart for 7AC.F
  • Previous Close 0.0131
  • Open 0.0131
  • Bid 0.0185 x --
  • Ask 0.0277 x --
  • Day's Range 0.0131 - 0.0185
  • 52 Week Range 0.0113 - 0.0461
  • Volume 40,000
  • Avg. Volume 1,612
  • Market Cap (intraday) 30.859M
  • Beta (5Y Monthly) 1.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.

www.acarix.com

--

Full Time Employees

December 30

Fiscal Year Ends

Recent News: 7AC.F

View More

Performance Overview: 7AC.F

Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

7AC.F
25.85%
OMX Stockholm 30 Index (^OMX)
12.38%

1-Year Return

7AC.F
14.35%
OMX Stockholm 30 Index (^OMX)
13.44%

3-Year Return

7AC.F
65.15%
OMX Stockholm 30 Index (^OMX)
2.06%

5-Year Return

7AC.F
71.57%
OMX Stockholm 30 Index (^OMX)
45.17%

Compare To: 7AC.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7AC.F

View More

Valuation Measures

Annual
As of 4/8/2025
  • Market Cap

    21.85M

  • Enterprise Value

    19.07M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    21.40

  • Price/Book (mrq)

    2.03

  • Enterprise Value/Revenue

    33.82

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -57.76%

  • Return on Equity (ttm)

    -103.76%

  • Revenue (ttm)

    6.2M

  • Net Income Avi to Common (ttm)

    -66.19M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    58.62M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -42.21M

Research Analysis: 7AC.F

View More

Company Insights: 7AC.F

Research Reports: 7AC.F

View More

People Also Watch